ESTRELLA IMMUNOPHARMA, INC. Deferred Income Tax Expense (Benefit)
ESTRELLA IMMUNOPHARMA, INC. (ESLA) reported Deferred Income Tax Expense (Benefit) of -$21.10 thousand for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-01.
Discontinued › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2023-08-01
- ESTRELLA IMMUNOPHARMA, INC. deferred income tax expense (benefit) for the quarter ending 2023-06-30 was $598.00.
- ESTRELLA IMMUNOPHARMA, INC. deferred income tax expense (benefit) for the quarter ending 2023-03-31 was -$21.70K.
- ESTRELLA IMMUNOPHARMA, INC. deferred income tax expense (benefit) for fiscal 2022 was $29.47K.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|---|---|
| 2023-06-30 | $598.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01 | -$21.10K 10-Q · filed 2023-08-01 | |
| 2023-03-31 | -$21.70K 10-Q · filed 2023-05-18 | ||
| 2022-12-31 | $29.47K 10-K · filed 2023-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |